Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
571 Eperisone HCl 50 mg Tablet M03BX09110T1001XX A Myotonic symptoms associated with cervical syndrome, periarthritis of shoulder and lumbago spastic paralysis 50 mg 3 times daily
572 Ephedrine HCl 30mg/ml Injection R03CA02-110-P30-01XXX B Treatment of bronchial spasm in asthma, adjunct to correct haemodynamic imbalances and treat hypotension in epidural and spinal anaesthesia None By IM, SC or IV. Severe, acute bronchospasm : 12.5-25 mg. Further dosage should be determine by patient response.
When used as a pressor agent : ADULT 25 - 50 mg SC/IM. If necessary, a second IM dose of 50 mg or an IV dose of 25 mg may be given.

Direct IV injection, 10 - 25 mg may be given slowly. Maximum parenteral ADULT dose : 150 mg in 24 hours. CHILD : 3 mg/kg or 100 mg/m2 SC or IV daily, in 4 - 6 divided doses
573 Epirubicin 2mg/mL Injection L01DB03-110-P40-02-XXX A* i. Solid tumour
ii. Non-Hodgkin's lymphoma
iii. Leukaemia (ALL induction)
iv. Lymphoma		 75 - 90mg/m2 body area injected IV in 3 - 5 min, repeated at 21 day intervals.Higher doses up to 135mg/m2 as single agent and 120mg/m2 as combination (effective in treatment of breast cancer) CHILD: 50 mg/m2 over 6 hours. Schedule depends on protocol.Refer to specific product for dosing information
574 Erlotinib 100 mg Tablet L01XE03-110-T10-03-XXX A* Second line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously failed one line of chemotherapy, and who have activating mutations of epidermal growth factor receptor (EGFR). Prescribing restrictions:
- Adenocarcinoma histology
- ECOG Performance Status 0-1
- Must be prescribed by an oncologist or oncology-trained respiratory physician.
- Must not have received prior TKI for this condition.		 150 mg taken at least one hour before or two hours after the ingestion of food once daily. Reduce in steps of 50 mg when necessary. Continue treatment until disease progression or unacceptable toxicity occurs. May require dose modifications when coadministered with strong CYP3A4 inhibitors or inducers; or in cigarette smoking patients.
575 Erlotinib 150 mg Tablet L01XE03-110-T10-02-XXX A* Second line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously failed one line of chemotherapy, and who have activating mutations of epidermal growth factor receptor (EGFR). Prescribing restrictions:
- Adenocarcinoma histology
- ECOG Performance Status 0-1
- Must be prescribed by an oncologist or oncology-trained respiratory physician.
- Must not have received prior TKI for this condition.		 150 mg taken at least one hour before or two hours after the ingestion of food once daily. Reduce in steps of 50 mg when necessary. Continue treatment until disease progression or unacceptable toxicity occurs. May require dose modifications when coadministered with strong CYP3A4 inhibitors or inducers; or in cigarette smoking patients.
576 Ertapenem 1g Injection J01DH03520P4001XX A* i) Patient with confirm ESBL producing gram-negative infection. ii) Empiric treatment for severe community acquired pneumonia or other infections when Pseudomonas aeruginosa is not suspected. ADULT: 1 g once daily. CHILD 3 month to 12 years: 15 mg/kg twice daily. Not to exceed 1 g/ day
577 Erythromycin Ethylsuccinate 200 mg/5 ml Suspension J01FA01-238-F21-01-XXX B Treatment of susceptible bacterial infections None Child: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.
578 Erythromycin Ethylsuccinate 400 mg Tablet J01FA01-238-T10-01-XXX B Treatment of susceptible bacterial infections none Adult 400 mg 6 hrly or 800 mg 12 hrly. Max: 4 g/day. Childn 30-50 mg/kg in divided doses. Childn 2-8 yr 1 g/day in divided doses in severe cases. Infant & childn ≤2 yr 500 mg/day in divided doses.
579 Erythromycin Ethylsuccinate 400 mg/5 ml Suspension J01FA01-238-F21-02-XXX B Treatment of susceptible bacterial infections None Child: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.
580 Erythromycin Lactobionate 500 mg Injection J01FA01-129-P30-01-XX A* Only for treatment of i) certain forms of meningitis ii) septicaemia not responding to usual antibiotics iii) mycoplasma pneumonia iv) infection with gram-positive organisms (e.g. tetanus, streptococcal infection) associated with Penicillin allergy, only when oral erythromycin cannot be given None Adult & Child: 25 - 50mg/kg /day infusion every 6 hours. Maximum: 4 g/day.
581 Erythropoietin Human Recombinant 10,000 IU Injection B03XA01-000-P50-05-XXX A* i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who have haemoglobin less than 10 g/dL or are exhibiting symptoms of anaemia although haemoglobin more than 10 g/dL and pre-transplant cases

ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy		 a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once weekly

b) EPO Beta: 450IU/kg once weekly or 30,000 IU once weekly

Dosing is according to product insert.
582 Erythropoietin Human Recombinant 1000 IU Injection B03XA01-000-P50-01-XXX A* i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who have haemoglobin less than 10 g/dL or are exhibiting symptoms of anaemia although haemoglobin more than 10 g/dL and pre-transplant cases

ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy		 a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once weekly

b) EPO Beta: 450IU/kg once weekly or 30,000 IU once weekly

Dosing is according to product insert.
583 Erythropoietin Human Recombinant 2000 IU Injection B03XA01-000-P50-02-XXX A i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who have haemoglobin less than 10 g/dL or are exhibiting symptoms of anaemia although haemoglobin more than 10 g/dL and pre-transplant cases

ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy		 a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once weekly

b) EPO Beta: 450IU/kg once weekly or 30,000 IU once weekly

Dosing is according to product insert.
584 Erythropoietin Human Recombinant 3000 IU Injection B03XA01-000-P50-03-XXX A* i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who have haemoglobin less than 10 g/dL or are exhibiting symptoms of anaemia although haemoglobin more than 10 g/dL and pre-transplant cases

ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy		 a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once weekly

b) EPO Beta: 450IU/kg once weekly or 30,000 IU once weekly

Dosing is according to product insert.
585 Erythropoietin Human Recombinant 4000 IU Injection B03XA01-000-P50-04-XXX A i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who have haemoglobin less than 10 g/dL or are exhibiting symptoms of anaemia although haemoglobin more than 10 g/dL and pre-transplant cases

ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy		 a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once weekly

b) EPO Beta: 450IU/kg once weekly or 30,000 IU once weekly

Dosing is according to product insert.
586 Escitalopram 10mg Tablet N06AB10-124-T10-01-XXX B i) Major depression
ii) Treatment of panic disorder with or without agoraphobia
iii) Treatment of social anxiety disorder (social phobia)
iv) Treatment of obsessive-compulsive disorder (OCD)
v) Treatment of generalised anxiety disorder		 None i) Initial: 10mg once daily.
Increase gradually if necessary up to a maximum of 20mg daily

ii) Initial: 5mg daily for the first week and then increase to 10mg daily Increase if necessary up to a maximum of 20mg daily
ELDERLY
Initial: half the adult dose, lower maximum dose should be considered

iii) Usual dose: 10mg once daily
Adjust as necessary based on patient response to either 5mg or up to a maximum of 20mg daily

iv) & v)
Usual dose: 10mg once daily
Adjust as necessary based on patient response up to a maximum of 20mg daily

Dosing is individualised and according to product insert/ protocol.
Should not be used in patients under 18 years old. If, based on clinical need, a decision to treat is nevertheless taken; the patient should be carefully monitored for appearance of suicidal symptoms.
587 Esmolol HCl 10mg/ml Injection C07AB09-110-P30-01-XX A* i) Supraventricular tachycardia
ii) Intraoperative and postoperative tachycardia and/or hypertension		 None i) & ii)
50-200 mcg/kg/min

Dosing is invidualised and according to product insert/protocol.
588 Esomeprazole 20 mg Tablet A02BC05-000-T10-02-XXX A i) Gastro-oesophageal reflux disease
ii) H. pylori eradication		 - First-line therapy for patients on Ryle’s tube or unable to tolerate oral therapy
- Second-line therapy for patients who are not suitable to take or did not respond well to pantoprazole despite optimal duration of treatment		 i) 20mg daily for 4-8 weeks
ii) 40mg daily for 10 days in combination with amoxicillin 1g twice daily or clarithromycin 500mg twice daily
589 Esomeprazole 40 mg Injection A02BC05-000-P30-01-XXX A* i) Acute erosive/ ulcerative oesophagitis
ii) Non-variceal upper gastrointestinal bleeding		 - i) 20- 40 mg once daily for 2-5 days
ii) 80 mg by IV bolus followed by 8mg/hour infusion for 72 hours
590 Esomeprazole 40 mg Tablet A02BC05-000-T10-01-XXX A i) Gastro-oesophageal reflux disease
ii) H. pylori eradication		 - First-line therapy for patients on Ryle’s tube or unable to tolerate oral therapy
- Second-line therapy for patients who are not suitable to take or did not respond well to pantoprazole despite optimal duration of treatment		 i) 20mg daily for 4-8 weeks
ii) 40mg daily for 10 days in combination with amoxicillin 1g twice daily or clarithromycin 500mg twice daily
591 Essential Phospholipids, nicotinamide, cyanocobalamine, tocopheryl, pyridoxine, thiamine, riboflavine capsule A05BA00-924-C10-01-XXX A/KK Nutritional support in the management of damaged liver (due to chronic liver disease, liver cirrhosis, fatty liver & intoxication by hepatotoxic substances). - 1-2 capsules 3 times a day
592 Estradiol 1mg & Estradiol 1mg with Dydrogesterone 10mg Tablet G03FB08-954-T10-01-XXX A* Hormone Replacement Therapy for women with disorders due to natural or surgically induced menopause with intact uterus. None One tablet daily without pill-free interval, starting with 1 mg of Estradiol for first 14 days, followed by 1mg Estradiol with 10 mg Dydrogestrone daily for the next 14 days
593 Estradiol 1mg with Dydrogesterone 5mg Tablet G03FB08-954-T10-02-XXX A* i) Hormone replacement therapy for the relief of symptoms due to oestrogen deficiency in women with a uterus
ii) Prevention of postmenopausal osteoporosis in women with a uterus		 None One tablet is to be taken daily for a 28-day cycle.
594 Estradiol Valerate 1mg Tablet G03CA03-256-T10-02-XXX A* i. Hormone replacement therapy (HRT) for the treatment of signs and symptoms of estrogen deficiency due to natural menopause or castration.
ii. Prevention of postmenopausal osteoporosis.		 None 1-2 mg daily continuously. Titrate to the minimum effective dose necessary to control symptoms.
595 Estradiol Valerate 2mg and Norgestrel 500mcg with Estradiol Valerate 2mg Tablet G03FB01-953-T10-01-XXX B i. Hormone replacement therapy (HRT) for the treatment of signs and symptoms of estrogen deficiency due to menopause or hypogonadism, castration or primary ovarian failure in women with an intact uterus.
ii. Prevention of postmenopausal osteoporosis.
iii. Control of irregular menstrual cycles.
iv. Treatment of primary or secondary amenorrhea.		 None One white tablet daily for the first 11 days, followed by one light brown tablet daily for 10 days then stop for a 7- day tablet-free interval before commencing next pack.
596 Etanercept 25 mg Injection L04AA11-000-P40-01-XXX A* i) Moderately to severe rheumatoid arthritis as monotherapy or in combination with methotrexate in patients with inadequate response to methotrexate alone.
ii) Active polyarticular-course juvenile idiopathic arthritis in children 2-17 years with inadequate response to, or who have proved intolerant of methotrexate.
iii) Psoriatic arthritis as monotherapy or in combination with methotrexate in patients inadequate response to methotrexate alone.
iv) Active ankylosing spondylitis in adults		 Adult & geriatric dose:
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis; 50 mg SC once-weekly for once-weekly dosing or 25 mg SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing.

Paediatric dose (2 to 17 years):
Juvenile idiopathic arthritis; 0.8 mg/kg (max. 25 mg/dose) SC once weekly for once-weekly dosing or 0.4 mg/kg (max. 25 mg/dose) SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing.
597 Etanercept 50 mg Injection L04AB01-000-P40-02-XXX A* i) Moderately to severe rheumatoid arthritis as monotherapy or in combination with methotrexate in patients with inadequate response to methotrexate alone.
ii) Active polyarticular-course juvenile idiopathic arthritis in children 2-17 years with inadequate response to, or who have proved intolerant of methotrexate.
iii) Psoriatic arthritis as monotherapy or in combination with methotrexate in patients inadequate response to methotrexate alone.
iv) Active ankylosing spondylitis in adults		 Adult & geriatric dose:
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis; 50 mg SC once-weekly for once-weekly dosing or 25 mg SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing.

Paediatric dose (2 to 17 years):
Juvenile idiopathic arthritis; 0.8 mg/kg (max. 25 mg/dose) SC once weekly for once-weekly dosing or 0.4 mg/kg (max. 25 mg/dose) SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing.
598 Ethambutol HCl 200 mg Tablet J04AK02-110-T10-01-XXX B Tuberculosis None Adult: 15-25mg/kg daily (max 1200mg) or 50mg/kg biweekly (max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice weekly.
599 Ethambutol HCl 400 mg Tablet J04AK02-110-T10-02-XXX B Tuberculosis None Adult: 15-25mg/kg daily (max 1200mg) or 50mg/kg biweekly (max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice weekly.
600 Ether Solvent N01AA01000L9901XX C To remove adhesive plaster from the skin Dose depending on the route and procedure

Pages